Medical Equipment/Supplies/Accessories · Founded 1993 · www.holmarc.com · NSE · ISIN INE0LXA01019
No Notes Added Yet
Business
Holmarc Opto-Mechatronics Ltd. is an Indian company specializing in the design, development, and manufacturing of precision opto-mechatronic products and systems. Its core business revolves around integrating optics, mechanics, and electronics to create high-tech solutions. While the sector indicates Medical Equipment, its expertise in opto-mechatronics suggests a broader application base including scientific research, industrial automation, and potentially defense, in addition to medical diagnostics and treatment devices. The company generates revenue by selling its manufactured products and potentially offering related services like installation, calibration, and maintenance to various clients.
Revenue Mix
Detailed segment-wise revenue breakdown is not readily available. However, based on its name and sector, Holmarc likely operates within:
Medical Equipment: Manufacturing devices for diagnostics, imaging, therapy, or laboratory applications that require optical and precision mechanical components.
Scientific & Research Instruments: Supplying specialized equipment to research institutions, universities, and laboratories.
Industrial Automation & Photonics: Providing components or systems for industrial processes requiring precision motion, optical sensing, or laser technology.
Given the company's stated sector, medical equipment is a significant focus area, though other segments contribute to its diversified product portfolio.
Industry
Holmarc operates within the Indian medical equipment and precision instrumentation industry. This industry is characterized by:
Growth Potential: Driven by increasing healthcare expenditure, a rising burden of non-communicable diseases, and government initiatives like "Make in India" and PLI schemes for medical devices.
High Import Dependency: India traditionally imports a significant portion of its medical equipment, especially high-end devices.
Competition: It faces competition from large multinational corporations (MNCs) that have established global presence and extensive R&D, as well as a growing number of domestic manufacturers.
Holmarc positions itself as a domestic player with specialized R&D and manufacturing capabilities in opto-mechatronics, aiming to reduce India's reliance on imported precision instruments and medical devices by offering indigenous solutions. It likely caters to niche markets requiring custom solutions or specific technological expertise.
MOAT
Holmarc's potential competitive advantages include:
Specialized Expertise: A deep understanding and capability in the niche field of opto-mechatronics, which requires highly specialized engineering and integration skills. This can be a barrier to entry for general manufacturers.
Indigenous R&D and Manufacturing: Its ability to design and manufacture products locally can offer cost advantages, faster customization, and better after-sales support compared to imports, especially for government tenders emphasizing local procurement.
Customer Relationships: Building long-term relationships with research institutions, hospitals, and industrial clients by providing reliable and customized solutions.
Product Diversification: A presence across multiple high-tech segments (medical, research, industrial) can provide revenue stability and reduce dependence on a single market.
Growth Drivers
Key factors that can drive Holmarc's growth over the next 3-5 years include:
Increasing Healthcare Expenditure: Growing demand for advanced medical equipment in India, particularly for diagnostics and specialized therapies.
Government Support: "Make in India" and Production Linked Incentive (PLI) schemes for medical devices encourage domestic manufacturing and reduce import dependency.
Technological Advancements: Continuous innovation in optical systems, precision mechanics, and electronics creating new applications and demand for sophisticated instruments.
Export Opportunities: Leveraging its specialized capabilities to tap into global markets, particularly in developing economies seeking cost-effective precision instruments.
Expansion into New Applications: Applying its core opto-mechatronics expertise to emerging sectors like aerospace, defense, or advanced manufacturing.
Risks
Holmarc faces several business risks:
Intense Competition: From well-established global players with superior R&D budgets and market reach, as well as local competitors.
Technological Obsolescence: The rapid pace of technological change in opto-mechatronics and medical devices requires continuous investment in R&D to stay relevant.
Regulatory Hurdles: The medical device industry is highly regulated, requiring stringent quality control, certifications, and compliance, which can be time-consuming and costly.
Supply Chain Dependencies: Reliance on imported components or critical raw materials can expose the company to supply disruptions and currency fluctuations.
Capital Intensity: R&D, advanced manufacturing facilities, and intellectual property development require significant capital investment.
Pricing Pressure: Competition and the cost-sensitive nature of the Indian market can lead to pricing pressures, impacting margins.
Management & Ownership
Holmarc Opto-Mechatronics Ltd. is likely a promoter-driven company, typical for many Indian SMEs in specialized manufacturing. The promoters, often founders, typically hold a significant equity stake, indicating a strong commitment to the company's long-term vision and operations. Management quality would be reflected in their ability to navigate a technically complex and competitive landscape, foster innovation, and scale operations effectively while adhering to regulatory standards. Given the nature of the business, a strong technical leadership background is often crucial.
Outlook
Holmarc Opto-Mechatronics operates in a promising yet challenging domain. The bull case for the company rests on India's burgeoning healthcare sector, government emphasis on indigenous manufacturing ("Make in India"), and the increasing demand for high-precision instrumentation across various sectors. Its specialized expertise in opto-mechatronics positions it to capture opportunities arising from technological advancements and a drive towards self-reliance in critical equipment.
Conversely, the bear case highlights intense competition from global giants, the high capital intensity of R&D and manufacturing, and the risk of technological obsolescence. Navigating stringent regulatory requirements and managing complex supply chains efficiently are also ongoing challenges. The company's future success will depend on its ability to continually innovate, effectively commercialize new products, expand its market reach, and maintain a cost-competitive edge while upholding quality standards in a demanding industry.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 16 | 21 | 29 | 33 | 37 | |
| Other Income | 0 | 0 | 0 | 0 | 1 | |
| Total Income | 16 | 21 | 29 | 34 | 38 | |
| Total Expenditure | 14 | 18 | 24 | 28 | 31 | |
| Operating Profit | 2 | 3 | 5 | 6 | 6 | |
| Interest | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | |
| Exceptional Income / Expenses | -0 | 0 | 1 | 0 | 0 | |
| Profit Before Tax | 1 | 2 | 5 | 5 | 5 | |
| Provision for Tax | 0 | 1 | 1 | 1 | 1 | |
| Profit After Tax | 1 | 2 | 4 | 3 | 4 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 1 | 2 | 4 | 3 | 4 | |
| Adjusted Earnings Per Share | 1 | 2.2 | 4.9 | 3.4 | 3.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 12% | 21% | 0% | 0% |
| Operating Profit CAGR | 0% | 26% | 0% | 0% |
| PAT CAGR | 33% | 26% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -14% | NA% | NA% | NA% |
| ROE Average | 15% | 23% | 20% | 20% |
| ROCE Average | 20% | 30% | 26% | 26% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | 7 | 8 | 12 | 24 | 27 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 1 | 1 | 0 | 0 |
| Other Non-Current Liabilities | 2 | 2 | 1 | 1 | 1 |
| Total Current Liabilities | 3 | 3 | 3 | 2 | 3 |
| Total Liabilities | 12 | 14 | 16 | 27 | 31 |
| Fixed Assets | 4 | 5 | 5 | 6 | 7 |
| Other Non-Current Assets | 1 | 0 | 0 | 0 | 1 |
| Total Current Assets | 7 | 8 | 11 | 20 | 23 |
| Total Assets | 12 | 14 | 16 | 27 | 31 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 | 2 | 2 | 9 |
| Cash Flow from Operating Activities | 0 | 3 | 2 | 2 | 3 |
| Cash Flow from Investing Activities | -1 | -2 | -0 | -2 | -2 |
| Cash Flow from Financing Activities | 0 | 0 | -1 | 7 | -0 |
| Net Cash Inflow / Outflow | 0 | 1 | 1 | 7 | 1 |
| Closing Cash & Cash Equivalent | 1 | 2 | 2 | 9 | 9 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.96 | 2.16 | 4.95 | 3.42 | 3.72 |
| CEPS(Rs) | 1.71 | 3.04 | 6.13 | 4.33 | 5.06 |
| DPS(Rs) | 0.28 | 0.28 | 0.3 | 0.4 | 0.4 |
| Book NAV/Share(Rs) | 9.56 | 11.44 | 16.11 | 23.72 | 27.03 |
| Core EBITDA Margin(%) | 9.69 | 13.88 | 17.53 | 15.88 | 15.7 |
| EBIT Margin(%) | 7.38 | 11.59 | 17.65 | 14.3 | 13.54 |
| Pre Tax Margin(%) | 6.27 | 10.52 | 16.58 | 13.67 | 13.28 |
| PAT Margin (%) | 4.43 | 7.38 | 12.27 | 10.26 | 10.05 |
| Cash Profit Margin (%) | 7.91 | 10.41 | 15.19 | 13 | 13.68 |
| ROA(%) | 5.83 | 12.04 | 23.72 | 15.91 | 12.81 |
| ROE(%) | 9.99 | 20.52 | 35.91 | 19.38 | 14.65 |
| ROCE(%) | 13.4 | 25.85 | 44.11 | 26.03 | 19.74 |
| Receivable days | 119.44 | 83.99 | 67.39 | 71.64 | 73.17 |
| Inventory Days | 23.58 | 22.61 | 23.32 | 27.03 | 38.12 |
| Payable days | 43.1 | 23.34 | 17.43 | 18.44 | 22.1 |
| PER(x) | 0 | 0 | 0 | 23.6 | 37.39 |
| Price/Book(x) | 0 | 0 | 0 | 3.4 | 5.14 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.5 | 0.29 |
| EV/Net Sales(x) | 0.07 | 0.03 | 0.22 | 2.15 | 3.5 |
| EV/Core EBITDA(x) | 0.62 | 0.22 | 1.2 | 12.64 | 20.4 |
| Net Sales Growth(%) | 0 | 35.37 | 38.12 | 15.24 | 11.08 |
| EBIT Growth(%) | 0 | 112.7 | 110.35 | -6.61 | 5.16 |
| PAT Growth(%) | 0 | 125.57 | 129.49 | -3.61 | 8.81 |
| EPS Growth(%) | 0 | 125.55 | 129.49 | -30.95 | 8.81 |
| Debt/Equity(x) | 0.24 | 0.25 | 0.12 | 0 | 0 |
| Current Ratio(x) | 2.61 | 3.16 | 4.13 | 9.42 | 7.67 |
| Quick Ratio(x) | 2.24 | 2.53 | 3.32 | 8.09 | 6.04 |
| Interest Cover(x) | 6.65 | 10.88 | 16.52 | 22.4 | 51.36 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 62.69 | 62.69 | 62.69 | 62.69 | 62.69 | 62.69 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.93 | 0 | 0 | 0 | 0.02 | 0 |
| Public | 36.39 | 37.31 | 37.31 | 37.31 | 37.29 | 37.31 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.01 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.37 | 0.38 | 0.38 | 0.38 | 0.37 | 0.38 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +12% | +21% | — | — |
| Operating Profit CAGR | 0% | +26% | — | — |
| PAT CAGR | +33% | +26% | — | — |
| Share Price CAGR | -14% | — | — | — |
| ROE Average | +15% | +23% | +20% | +20% |
| ROCE Average | +20% | +30% | +26% | +26% |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 62.69 | 62.69 | 62.69 | 62.69 | 62.69 | 62.69 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.93 | 0 | 0 | 0 | 0.02 | 0 |
| Public | 37.31 | 37.31 | 37.31 | 37.31 | 37.31 | 37.31 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.01 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.